Immunic (IMUX) Stock Forecast, Price Target & Predictions
IMUX Stock Forecast
Immunic stock forecast is as follows: an average price target of $5.00 (represents a 179.33% upside from IMUX’s last price of $1.79) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
IMUX Price Target
The average price target for Immunic (IMUX) is $5.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 179.33% upside from IMUX's last price of $1.79.
IMUX Analyst Ratings
According to 6 Wall Street analysts, Immunic's rating consensus is 'Buy'. The analyst rating breakdown for IMUX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Immunic Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 21, 2022 | Market Perform | Leerink Partners | $5.00 | $2.08 | 139.81% | 179.33% |
The latest Immunic stock forecast, released on Oct 21, 2022 by Market Perform from Leerink Partners, set a price target of $5.00, which represents a 139.81% increase from the stock price at the time of the forecast ($2.08), and a 179.33% increase from IMUX last price ($1.79).
Immunic Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.79 | $1.79 | $1.79 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Immunic stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immunic's last price of $1.79. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | EF Hutton | - | Buy | Initialise |
| Sep 04, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 27, 2024 | B. Riley | - | Buy | Initialise |
| Jul 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 05, 2024 | Brookline Capital | - | Buy | Initialise |
| Oct 21, 2022 | SVB Leerink | - | Market Perform | Downgrade |
| Jun 10, 2022 | Roth Capital | Buy | Buy | Hold |
Immunic's last stock rating was published by EF Hutton on Sep 16, 2024. The company Initialise its IMUX rating from "null" to "Buy".
Immunic Financial Forecast
Immunic Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $470.77M | $452.66M | $452.66M | $434.56M | - | - | - | - | $6.00K | $6.00K | - |
| High Forecast | $470.77M | $452.66M | $452.66M | $434.56M | - | - | - | - | $6.00K | $6.00K | - |
| Low Forecast | $470.77M | $452.66M | $452.66M | $434.56M | - | - | - | - | $6.00K | $6.00K | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Immunic's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMUX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Immunic EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict IMUX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immunic's previous annual EBITDA (undefined) of $NaN.
Immunic Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-18.57M | $-18.57M | $-17.55M | $-21.60M | $-21.44M | $-22.11M | $-23.55M |
| High Forecast | - | - | - | - | $-18.57M | $-18.57M | $-17.55M | $-21.60M | $-21.44M | $-22.11M | $-23.55M |
| Low Forecast | - | - | - | - | $-18.57M | $-18.57M | $-17.55M | $-21.60M | $-21.44M | $-23.12M | $-23.55M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Immunic's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMUX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Immunic SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Immunic's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMUX last annual SG&A of $NaN (undefined).
Immunic EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-0.18 | $-0.18 | $-0.17 | $-0.21 | $-0.21 | $-0.22 | $-0.23 |
| High Forecast | - | - | - | - | $-0.18 | $-0.18 | $-0.17 | $-0.21 | $-0.21 | $-0.22 | $-0.23 |
| Low Forecast | - | - | - | - | $-0.18 | $-0.18 | $-0.17 | $-0.21 | $-0.21 | $-0.23 | $-0.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Immunic's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMUX previous annual EPS of $NaN (undefined).
Immunic Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.58 | $17.50 | 2917.24% | Buy |
| KRON | Kronos Bio | $0.92 | $7.63 | 729.35% | Buy |
| STTK | Shattuck Labs | $3.65 | $12.00 | 228.77% | Buy |
| IMUX | Immunic | $1.79 | $5.00 | 179.33% | Buy |
| EWTX | Edgewise Therapeutics | $19.07 | $48.00 | 151.70% | Buy |
| ERAS | Erasca | $2.89 | $7.00 | 142.21% | Buy |
| FHTX | Foghorn Therapeutics | $9.56 | $18.00 | 88.28% | Buy |
| CCCC | C4 Therapeutics | $6.38 | $11.33 | 77.59% | Hold |
| NRIX | Nurix Therapeutics | $24.74 | $27.57 | 11.44% | Buy |
| KYMR | Kymera Therapeutics | $46.44 | $51.10 | 10.03% | Buy |
IMUX Forecast FAQ
Is Immunic a good buy?
Yes, according to 6 Wall Street analysts, Immunic (IMUX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of IMUX's total ratings.
What is IMUX's price target?
Immunic (IMUX) average price target is $5 with a range of $5 to $5, implying a 179.33% from its last price of $1.79. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Immunic stock go up soon?
According to Wall Street analysts' prediction for IMUX stock, the company can go up by 179.33% (from the last price of $1.79 to the average price target of $5), up by 179.33% based on the highest stock price target, and up by 179.33% based on the lowest stock price target.
Can Immunic stock reach $3?
IMUX's average twelve months analyst stock price target of $5 supports the claim that Immunic can reach $3 in the near future.
What are Immunic's analysts' financial forecasts?
Immunic's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-76.291M (high $-76.291M, low $-76.291M), average SG&A $0 (high $0, low $0), and average EPS is $-0.753 (high $-0.753, low $-0.753). IMUX's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $1.81B (high $1.81B, low $1.81B), average EBITDA is $0 (high $0, low $0), average net income is $0 (high $0, low $0), average SG&A $0 (high $0, low $0), and average EPS is $0 (high $0, low $0).